ESHHAR Z ET AL: "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 90, no. 2, 15 January 1993 (1993-01-15), pages 720-724, XP002579936, ISSN: 0027-8424, DOI: 10.1073/PNAS.90.2.720 cited in the application (B1)

KOCHENDERFER JAMES N ET AL: "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", BLOOD, vol. 116, no. 20, November 2010 (2010-11), pages 4099-4102, XP002667047, cited in the application (B1)

MONTSERRAT E ET AL: "Chronic lymphocytic leukaemia treatment", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, vol. 7, no. 3, 1 September 1993 (1993-09-01), pages 164-175, XP022954383, ISSN: 0268-960X, DOI: 10.1016/0268-960X(93)90003-M [retrieved on 1993-09-01] cited in the application (B1)

Rosenberg SA: "Treatment of B Cell Malignancies with T Cells Expressing an Anti-CD19 ChimericReceptor: Assessment of the Impact of Lymphocyte Depletion Prior to T CellTransfer", , September 2008 (2008-09), XP002667046, Retrieved from the Internet: URL:http://www.gemcris.od.nih.gov/Abstract s/940_s.pdf [retrieved on 2012-01-13] cited in the application (B1)

SADELAIN MICHEL ET AL: "The promise and potential pitfalls of chimeric antigen receptors", CURRENT OPINION IN IMMUNOLOGY, vol. 21, no. 2, April 2009 (2009-04), pages 215-223, XP002667114, ISSN: 0952-7915 cited in the application (B1)

WO-A2-2005/012493 (B1)

US-A1- 2011 104 150 (B1)

WO-A1-00/74718 (B1)

WO-A1-2007/064911 (B1)

WO-A1-2007/076950 (B1)

WO-A1-2011/018225 (B1)

SCHEUERMANN R H ET AL: "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.", LEUKEMIA & LYMPHOMA AUG 1995 LNKD- PUBMED:8528044, vol. 18, no. 5-6, August 1995 (1995-08), pages 385-397, XP009155469, ISSN: 1042-8194 cited in the application (B1)